Shuren Highlights CDRH Actions To Ease Trial Burdens On Capitol Hill-thegraysheet: Jeffrey Shuren emphasized recent efforts by FDA’s device center to reduce premarket clinical trial burdens in return for strong postmarket controls during the May 6 inaugural roundtable of the House Energy and Commerce Committee’s “21st Century Cures” initiative. Shuren also put his support behind clinical trial networks as a strategy to speed data gathering during the session on Capitol Hill, which lawmakers organized to identify strategies for accelerating the development of new medical treatments.
